(Reuters) – Healthcare investment firm Syncona Ltd said on Wednesday Novartis AG will buy its Gyroscope Therapeutics unit for up to $1.5 billion as the Swiss drugmaker seeks access to the British firm’s gene therapy for a blindness-causing disease.
(Reporting by Sinchita Mitra and Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
